DDrare: Database of Drug Development for Rare Diseases

Searched query = "Stevens-Johnson syndrome", "SJS", "Mucocutaneous ocular syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 0.05%cyclosporin eye drop; 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine; Cultivated oral mucosal epithelial sheet transplantation; Cyclosporin; Cyclosporine; Cyclosporine 5 mg/kg bid days 0-14; Etanercept; Etanercept 50 mg sc day 0 and day 3; Harmonized supportive care; Infliximab; Intravenous immunoglobulin; Lamotrigine; Lamotrigine - generic product; Methylprednisolone; Palifermin; Prednisolone; Riboflavin; Site specific standard of care comparison; Topical infliximab

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02126020 (ClinicalTrials.gov)	November 2014	27/4/2014	Topical Infliximab in Autoimmune Eyes With Keratoprosthesis	Topical Infliximab in Autoimmune Eyes With Keratoprosthesis	Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis (Lyell) Syndrome;Mucous Membrane Pemphigoid	Drug: topical infliximab	James Chodosh, MD, MPH	Massachusetts Eye and Ear Infirmary;Fonds de recherche en ophtalmologie de l'Université de Montréal (FROUM)	Withdrawn	18 Years	80 Years	All	0	Phase 1;Phase 2	United States;Canada
2	NCT01256489 (ClinicalTrials.gov)	December 2010	19/11/2010	Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)	Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis	Stevens-Johnson Syndrome;Corneal Blindness	Drug: Infliximab	Massachusetts Eye and Ear Infirmary	NULL	Withdrawn	18 Years	N/A	Both	0	Phase 1;Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02126020
(ClinicalTrials.gov)

November 2014

27/4/2014

Topical Infliximab in Autoimmune Eyes With Keratoprosthesis

Stevens-Johnson Syndrome;Toxic Epidermal Necrolysis (Lyell) Syndrome;Mucous Membrane Pemphigoid

Drug: topical infliximab

James Chodosh, MD, MPH

Massachusetts Eye and Ear Infirmary;Fonds de recherche en ophtalmologie de l'Université de Montréal (FROUM)

Withdrawn

18 Years

80 Years

All

Phase 1;Phase 2

United States;Canada

NCT01256489
(ClinicalTrials.gov)

December 2010

19/11/2010

Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)

Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis

Stevens-Johnson Syndrome;Corneal Blindness

Drug: Infliximab

Massachusetts Eye and Ear Infirmary

NULL

Withdrawn

18 Years

N/A

Both

Phase 1;Phase 2

United States